{"title": "Understanding the present status and forecasting of COVID\u201519 in Wuhan", "doi": "10.1101/2020.02.13.20022251", "citation_id": "2020.02.13.20022251v1", "date": "2020-02-14", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.02.13.20022251", "abstract": "<p>The present status of COVID\u201519 is analyzed and the end of the disease is forecasted. The peak of the epidemic is different in three regions, Wuhan, Hubei province except Wuhan, and mainland China except Hubei. In two regions except Wuhan, the peak of the epidemic passed ten days ago. If the trend until February 11 does not change, the disease may end by the end of February. In Wuhan, the epidemic reached a peak but the reported number of newly infected patients fluctuates largely. We need to know the reason for the big fluctuation to forecast the end of the disease.</p>", "twitter_description": "The present status of COVID\u201519 is analyzed and the end of the disease is forecasted. The peak of the epidemic is different in three regions, Wuhan, Hubei province except Wuhan, and mainland China except Hubei. In two regions except Wuhan, the peak of the epidemic passed ten days ago. If the trend until February 11 does not change, the disease may end by the end of February. In Wuhan, the epidemic reached a peak but the reported number of newly infected patients fluctuates largely. We need to know the reason for the big fluctuation to forecast the end of the disease.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nNo external funding was received\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nAll the data used in the manuscript are available from references.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.02.13.20022251v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.02.13.20022251v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.02.13.20022251v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/02/14/2020.02.13.20022251.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.02.13.20022251v1", "access_rights": "restricted", "authors": ["Toshihisa Tomie"]}